BLUEMTEC Co., Ltd (439580) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of BLUEMTEC Co., Ltd stock KRW 2,611, price KRW 1,822, upside +43.3%, quality 44 out of 100. Rating: undervalued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
35‑month range 1,466 KRW – 17,000 KRW · fair‑value band 1,774 KRW – 4,276 KRW · the 1,822 KRW price screens below the 2,611 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow BLUEMTEC Co. in your weekly email
Every Wednesday you see whether BLUEMTEC Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BLUEMTEC Co., Ltd. operates a pharmaceutical distribution platform in South Korea and internationally. It is also involved in the healthcare digital marketing, IT development, fulfilment, pharmaceutical distribution data, and medical staff matching, and logistics businesses.
Show moreShow less
The company was founded in 2015 and is headquartered in Yongin-si, South Korea.
Stock analysis
BLUEMTEC Co., Ltd (439580) currently trades at 1,822 KRW, while our model-based Fair Value estimate is 2,611 KRW, implying the stock looks roughly 30% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 4,276 KRW per share, and 6 of the 9 models we run sit above the 1,822 KRW price.
Bear case: the Multiples group reads lowest at 528.95 KRW, and 3 of the 9 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 1,774 KRW (bear) to 4,276 KRW (bull), the price of 1,822 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BLUEMTEC Co., Ltd reported revenue of 186B KRW in FY2025 versus 51.9B KRW in FY2021, a compound +37.6%/yr. Reported net income was −4.5B KRW in FY2025.
Key figures
Market cap 67.6B KRW (≈ $50.0M) Micro · P/E ratio 14.7 · P/S ratio 0.33 · EPS (TTM) 125.78 KRW · Net margin 2.1% · Return on equity 9.2% · Return on assets (EBIT) −2.9% (5-year average) · Operating margin 0.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 24% fair-value upside, at 43%, 439580 screens cheaper than that median.
Fair Value models
Bear1,774 KRWFair Value 2,611 KRWBull4,276 KRW
Price 1,822 KRW · Upside +43.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (107.86 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+39.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.1%
’21
’22
’23
’24
’25
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +9.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Bottom 25%
Fair Value upside+43.3% · Above median
Profitability
Return on equity (12 months)9.2% · Above median
Return on assets−4.1% · Bottom 25%
Net margin (12 months)2.1% · Below median
Operating margin (12 months)0.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)20.4% · Top 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BLUEMTEC Co., Ltd (439580) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2,611 KRW versus a price of 1,822 KRW, about +43% upside (undervalued).
What is the fair value of 439580?
Our model-based fair value for BLUEMTEC Co., Ltd is 2,611 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 1,822 KRW.
What is the quality score of 439580?
BLUEMTEC Co., Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BLUEMTEC Co., Ltd (439580)?
Our model-based price target is the fair value of 2,611 KRW (as of Nov 9, 2026) from 9 valuation models. Cautious scenario 1,774 KRW, optimistic scenario 4,276 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the BLUEMTEC Co., Ltd stock forecast for 2026?
Our models put fair value at 2,611 KRW, about +43% upside versus a price of 1,822 KRW (undervalued). Cautious scenario 1,774 KRW, optimistic scenario 4,276 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of BLUEMTEC Co., Ltd (439580)?
BLUEMTEC Co., Ltd reported trailing-twelve-month revenue of about 205B KRW (latest available figure, as of Nov 9, 2026).
What growth is priced into BLUEMTEC Co., Ltd (439580)?
For today's price to be fair in a discounted-cash-flow model, BLUEMTEC Co., Ltd would have to grow free cash flow by +11.9 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +37.6 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 439580 use?
Our models discount BLUEMTEC Co., Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.52, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BLUEMTEC Co., Ltd that is +11.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has BLUEMTEC Co., Ltd (439580) delivered so far?
Over the past 4 years revenue at BLUEMTEC Co., Ltd grew +37.6 % a year. The price currently implies free-cash-flow growth of +11.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BLUEMTEC Co., Ltd (439580) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into BLUEMTEC Co., Ltd (+11.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BLUEMTEC Co., Ltd (439580)?
The free-cash-flow yield on the price is 4.93 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow BLUEMTEC Co., Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BLUEMTEC Co., Ltd (439580)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BLUEMTEC Co., Ltd it is 2,611 KRW per share (as of Nov 9, 2026), against a price of 1,822 KRW. It is the blended result of 9 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is BLUEMTEC Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 439580 trades below its calculated fair value: price 1,822 KRW, fair value 2,611 KRW, a gap of about +43% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 439580?
No. The price is what the market pays today (1,822 KRW); the fair value is what the company's own numbers justify (2,611 KRW). For BLUEMTEC Co., Ltd the two are 789.04 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is BLUEMTEC Co., Ltd worth?
The market values BLUEMTEC Co., Ltd at about 67.6B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 1,822 KRW; our models calculate a fair value of 2,611 KRW per share.
What do the bullish and bearish scenarios say about 439580?
Our models span a range for BLUEMTEC Co., Ltd: cautious scenario 1,774 KRW, base 2,611 KRW, optimistic 4,276 KRW per share (as of Nov 9, 2026, price 1,822 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 439580?
BLUEMTEC Co., Ltd trades at a price-to-earnings ratio of 14.7 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,611 KRW is built from several models across several years. Other multiples: P/B 1.5, P/S 0.3, EV/EBITDA 38.1.
How solid is the balance sheet of BLUEMTEC Co., Ltd (439580)?
Balance-sheet figures for BLUEMTEC Co., Ltd (as of Nov 9, 2026): return on equity 9.2%, debt of 0.02 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 439580 from its 52-week high?
BLUEMTEC Co., Ltd trades at 1,822 KRW, about 64% below its 52-week high of 5,130 KRW and 24% above the low of 1,466 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2,611 KRW is for.
Which stocks are comparable to BLUEMTEC Co., Ltd?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BLUEMTEC Co., Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 1,822 KRW, calculated fair value 2,611 KRW (+43%), Quality Score 44/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 439580 calculated?
We run BLUEMTEC Co., Ltd through 9 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 2,611 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BLUEMTEC Co., Ltd currently trades 30% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BLUEMTEC Co., Ltd (439580)?
The closing price on Nov 9, 2026 was 1,822 KRW. Our model-based fair value is 2,611 KRW, about +43% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BLUEMTEC Co., Ltd right now?
The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain. A fairly wide model range (1,774 KRW to 4,276 KRW) leaves room in how you read the outcome.
Key figures of BLUEMTEC Co., Ltd
How large is the market capitalisation of BLUEMTEC Co., Ltd (439580)?
The market capitalisation of BLUEMTEC Co., Ltd is 67.6B KRW (≈ $50.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BLUEMTEC Co., Ltd (439580)?
The price-to-sales ratio of BLUEMTEC Co., Ltd is 0.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BLUEMTEC Co., Ltd (439580)?
Earnings per share at BLUEMTEC Co., Ltd are 125.78 KRW (price ÷ EPS = P/E 14.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BLUEMTEC Co., Ltd (439580)?
The net margin of BLUEMTEC Co., Ltd is 2.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BLUEMTEC Co., Ltd (439580)?
The return on equity (ROE) of BLUEMTEC Co., Ltd is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BLUEMTEC Co., Ltd (439580)?
On an EBIT basis the return on assets of BLUEMTEC Co., Ltd is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BLUEMTEC Co., Ltd (439580)?
The operating margin of BLUEMTEC Co., Ltd is 0.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BLUEMTEC Co., Ltd (439580)?
Revenue at BLUEMTEC Co., Ltd is growing +20.4% versus a year earlier (3y avg +34.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does BLUEMTEC Co., Ltd (439580) carry?
The net debt of BLUEMTEC Co., Ltd is 21.8B KRW (fiscal year 2025, ≈ 7.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BLUEMTEC Co., Ltd in the live analysis
One click puts BLUEMTEC Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026